FDA 483 OBSERVATION · #92 OF 1,945 MOST-CITED

Design Validation - Risk analysis not performed/inadequate

FDA cited this observation 307 times across 283 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices307
BY FISCAL YEAR
FY202618
FY202536
FY202435
FY202325
FY202228
FY202112
FY202014
FY201936
FY201840
FY201736
FY201627

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 820.30(g)

21 CFR 820.30 (Design controls) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Design and development”: ISO 13485 clause 7.3, with documented risk management in product realization (21 CFR 4.4(b)(1)).

Design validation did not include adequate risk analysis (or none was performed), so the device design was not evaluated for the hazards and risks it could present in actual use.

Why FDA writes it — Design validation must confirm the device is safe for its intended use, and risk analysis is how safety is demonstrated. Omitting or under-doing risk analysis means hazards go unidentified and uncontrolled in the design — a direct patient-safety gap FDA scrutinizes closely.

HOW TO COMPLY
  • Include risk analysis, where appropriate, as part of design validation.
  • Identify hazards and hazardous situations across intended use and foreseeable misuse, and evaluate and control the associated risks (aligned with ISO 14971).
  • Validate on production or equivalent units under actual or simulated use conditions.
  • Document residual risk and the overall benefit-risk conclusion, and update the risk file on design changes.
WHY FIRMS GET CITED
  • Risk analysis treated as a separate paperwork exercise, not integrated into design validation.
  • Analysis limited to component failures, missing use-related and foreseeable-misuse hazards.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 2.4× the rate of the average FDA-cited firm (18.4% vs 7.8%), across 283 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Risk analysis is inadequate and is incomplete.

DASISIMULATIONS, LLC · Dublin, Ohio · Devices · 2026-01-16

Risk analysis is inadequate.

Nuclein LLC · Austin, Texas · Devices · 2026-01-13

Risk analysis is inadequate.

Innova Vascular Inc · Irvine, California · Devices · 2026-01-12

Risk analysis is inadequate.

ZIIP INC · Pleasant Hill, California · Devices · 2026-01-12

Risk analysis is inadequate.

Excel Medical Electronics LLC · Palm Bch Gdns, Florida · Devices · 2025-12-19

Risk analysis is inadequate.

Black Diamond Video Inc. · Richmond, California · Devices · 2025-12-12

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk management →Medical devices →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →